Journal
MICROORGANISMS
Volume 9, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/microorganisms9071382
Keywords
multi-pathogen enteric vaccines; Shigella vaccine; ETEC vaccine; Campylobacter vaccine; mucosal immunity; disease burden; stunting; models of disease; adjuvants
Categories
Funding
- Bill and Melinda Gates Foundation [OPP1112376]
- United Kingdom's Foreign, Commonwealth, and Development Office [204139-101]
- National Institutes of Health, National Institutes of Allergy and Infectious Diseases (NIAID) [R01AI126887, R01AI089894]
- Department of Veterans Affairs [1I01BX004825]
- Bill and Melinda Gates Foundation [OPP1112376] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Vaccines targeting Shigella, ETEC, and Campylobacter could potentially reduce one-third of childhood diarrhea cases and address increasing antimicrobial resistance. The proposed vaccine combinations may meet the WHO's preferred product characteristics for ETEC and Shigella vaccines, and improve support from Gavi, the Vaccine Alliance, and LMIC public health stakeholders. Broadly protective antigens enable efficient and cost-effective development of multi-pathogen vaccines to combat a major cause of poor health and economic burden worldwide.
The global diarrheal disease burden for Shigella, enterotoxigenic Escherichia coli (ETEC), and Campylobacter is estimated to be 88M, 75M, and 75M cases annually, respectively. A vaccine against this target trio of enteric pathogens could address about one-third of diarrhea cases in children. All three of these pathogens contribute to growth stunting and have demonstrated increasing resistance to antimicrobial agents. Several combinations of antigens are now recognized that could be effective for inducing protective immunity against each of the three target pathogens in a single vaccine for oral administration or parenteral injection. The vaccine combinations proposed here would result in a final product consistent with the World Health Organization's (WHO) preferred product characteristics for ETEC and Shigella vaccines, and improve the vaccine prospects for support from Gavi, the Vaccine Alliance, and widespread uptake by low- and middle-income countries' (LMIC) public health stakeholders. Broadly protective antigens will enable multi-pathogen vaccines to be efficiently developed and cost-effective. This review describes how emerging discoveries for each pathogen component of the target trio could be used to make vaccines, which could help reduce a major cause of poor health, reduced cognitive development, lost economic productivity, and poverty in many parts of the world.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available